Overall verdict
Neutral
5.3/10
1-year performance
+40.57%
Score breakdown
Up 40.6% over 1 year, 100% of the 52-week range.
Strongest: Profitability 6.4/10. Weakest: Growth 2.7/10.
17 analysts, target +0.0% vs the price.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.
It also provides specialty testing services comprising gene-based and esoteric testing ; advanced tests target specific diseases ; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests ;
and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides ; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs ; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts ;
and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Adam Schechter
Founded
1995
Employees
71 000
Revenue / employee
196 503 USD
Next earnings
February 18, 2027 (estimated)
Institutional holders
- FMR LLC4.54%
- GEODE CAPITAL MANAGEMENT, LLC2.69%
- Bank of New York Mellon Corp0.61%
- Rest of the register92.16%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
373.76 USD
52-week low
245.00 USD
1-year performance
40.57%
Rising
Year-to-date performance
48.50%
Rising
Drawdown
-0.15%
Near its high
Position in the 52-week range
100% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned more, but shaking 1.7 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2000 are worth today
| Labcorp Holdings | $82,134 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.7 times as much as the world ETF.
- Worst fall:-53Â % between April 2002 and December 2002. $10,000 placed at the top fell to $4,685. The world ETF, at worst: -53Â %. Back to its high in 24 months.
Labcorp Holdings earned more than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Labcorp Holdings: $82,134
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 266.00 USD - 287.49 USD (comparables only)
The price implies growth of 7.13% per year; the company grows at -8.01%.
Gross margin 26.9%, net margin 6.9%, ROIC 6.8%, ROE 11.4%.
Net margin
6.88%
Exceptional
Sector 4.51%|S&P 13.40%
Gross margin
26.87%
Fair
Return on equity (ROE)
11.45%
Fair
Sector 10.36%|S&P 17.06%
Return on invested capital (ROIC)
6.84%
Fair
Free cash flow margin (FCF)
8.82%
Fair
Profit-to-cash conversion (FCF conversion)
1.28x
Fair
Margin stability
3.9 pts
Steady
Revenue to net income
Growth
2.7/10Revenue up 6.9% over 1 year, -0.0% a year over 5, EPS -8.0% a year over 5.
Revenue (trailing 12 months)
14.6Md USD
Revenue growth (1y)
6.92%
Moderate
Revenue growth (3y)
17.60%
Solid
EPS growth (1y)
3.24%
Moderate
EPS CAGR (5y)
-8.01%
Declining
EPS revisions (3 months)
0.62%
Revised up
Valuation
4.3/10P/E 30.6x, forward P/E 27.5x, EV/EBITDA 16.4x, PEG 1.55. The multiple sits in the 82th percentile of its own 5-year history.
P/E (TTM)
30.6x
Fair
Sector 27.0x|S&P 23.6x
Forward P/E
27.5x
Fair
EV / EBITDA
16.4x
Expensive
Sector 12.5x|S&P 15.5x
PEG
1.55
Expensive
Sector 0.67|S&P 0.91
Fair value (reverse DCF)
276.74 USD
Overvalued
P/E vs its own 5-year history
among the 18% highest valuations
At its historical high
Market cap
30.3Md USD
Financial strength
3.7/10Cash covers 3.9% of the debt, net debt/EBITDA 2.4x.
Net debt / EBITDA
2.4x
Tight
Gearing (net debt / equity)
73.49%
Tight
Cash
262M USD
Cash / market cap
0.86%
Stretched
Cash / total debt
3.86%
Stretched
Interest coverage
6.5x
Solid
Net debt
6.5Md USD
Equity
8.9Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 370.88 USD
- MM20344.29
- MM50327.15
- MM200290.88
- RSI 1471.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+3.12%
200-day average slope, 3 months
+7.90%
50-day average slope, 1 month
+2.25%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.35 % per day
Volatility change
+62.47%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 13.59 (8) | 18.49 (18) | 14 827 (16) | 2 613 (8) | 1 111 (6) |
| 2027 | 15.06 (8) | 19.60 (18) | 15 625 (16) | 2 763 (8) | 1 218 (6) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 5, 2026.
Same sub-industry: 76 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DVA | 6.6 | 6.5 | 11.5Md USD | 13.9x | 6.3 % | 4.6 % | 7.5 % | 4.5x | 11.2 % | 52.1 % | ||
| 2 | CVS | 6.5 | 6.0 | 115Md USD | 10.4x | 2.6 % | 5.4 % | 7.4 % | 4.1x | 13.6 % | 14.8 % | ||
| 3 | HNGE | 6.4 | 7.0 | 9.5Md USD | 61.3x | 20.7 % | 52.4 % | 44.7 % | -1.6x | 3.3 % | 171.5 % | ||
| 4 | DGX | 6.1 | 6.1 | 28.5Md USD | 25.8x | 9.5 % | 10.0 % | 8.4 % | 2.8x | 4.8 % | 39.8 % | ||
| 5 | CI | 6.1 | 6.1 | 79.4Md USD | 13.3x | 2.1 % | 5.7 % | 8.3 % | 1.8x | 10.4 % | 15.8 % | ||
| 6 | BTSG | 6.0 | 4.7 | 14.5Md USD | 47.2x | 2.0 % | 26.4 % | 7.0 % | 4.6x | 3.4 % | 116.3 % | ||
| 7 | FME | 5.4 | 5.4 | 12.0Md USD | 13.6x | 4.2 % | 1.1 % | 3.8 % | 2.7x | 17.0 % | -0.5 % | ||
| 8 | GH | 5.3 | 3.6 | 20.9Md USD | Not meaningful (loss) | -37.9 % | 36.1 % | -41.6 % | -1.4x | -1.1 % | 59.9 % | ||
| 9 | LH | 5.3 | 4.4 | 30.3Md USD | 30.6x | 6.9 % | 6.9 % | 6.8 % | 2.4x | 4.2 % | 40.6 % |
